{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:53:00Z","timestamp":1789390380951,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007658","name":"Baxter Healthcare Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007658","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.vaccine.2013.07.083","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T21:28:27Z","timestamp":1376083707000},"page":"4477-4486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Effectiveness of meningococcal serogroup C vaccine programmes"],"prefix":"10.1016","volume":"31","author":[{"given":"Ray","family":"Borrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona R.M.","family":"van der Klis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A.","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.07.083_bib0005","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1086\/315158","article-title":"The changing epidemiology of meningococcal disease in the United States, 1992\u20131996","volume":"180","author":"Rosenstein","year":"1999","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0010","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/CMR.13.1.144","article-title":"Update on meningococcal disease with emphasis on pathogenesis and clinical management","volume":"13","author":"van Deuren","year":"2000","journal-title":"Clinical Microbiology Reviews"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0020","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0025","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.2807\/ese.13.02.08008-en","article-title":"Outbreak of serogroup C meningococcal disease in Veneto region, Italy","volume":"13","author":"Ferro","year":"2008","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0030","unstructured":"European Centre for Disease Prevention and Control. Surveillance report on invasive bacterial disease in Europe for 2008\u20132009. European Centre for Disease Prevention and Control 2011 July 18. http:\/\/www.ecdc.europa.eu\/en\/press\/news\/Lists\/News\/ECDC_DispForm.aspx?List=32e43ee8%2De230%2D4424%2Da783%2D85742124029a&ID=464&RootFolder=%2Fen%2Fpress%2Fnews%2FLists%2FNews [accessed 22.03.13]"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2013.07.083_bib0035","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meninococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.8.3.265","article-title":"Prevention of meningococcal serogroup C disease by NeisVac-C","volume":"8","author":"Borrow","year":"2009","journal-title":"Expert Review of Vaccines"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0045","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","article-title":"Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain","volume":"23","author":"Larrauri","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4161\/hv.2.2.2611","article-title":"Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales","volume":"2","author":"Trotter","year":"2006","journal-title":"Human vaccines"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2013.07.083_bib0065","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0075","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0080","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Review of Vaccines"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0085","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/cid\/cir007","article-title":"Herd immunity: a rough guide","volume":"52","author":"Fine","year":"2011","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2567.2008.02934.x","article-title":"Plasma and memory B-cell kinetics in infants following a primary schedule of CRM-conjugated serogroup C meningococcal polysaccharide vaccine","volume":"127","author":"Kelly","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0095","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/blood-2006-01-009282","article-title":"CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells","volume":"108","author":"Kelly","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0100","first-page":"794","article-title":"Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine","volume":"56","year":"2007","journal-title":"MMWR \u2013 Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0105","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine","volume":"17","author":"Borrow","year":"2010","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0110","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/INF.0b013e3181d9e653","article-title":"Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2249.2000.01109.x","article-title":"Conjugate vaccines","volume":"119","author":"Goldblatt","year":"2000","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0120","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/jama.1992.03480110065035","article-title":"Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group","volume":"267","author":"Schlesinger","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0125","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/S0264-410X(98)00458-7","article-title":"Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood","volume":"17","author":"Anttila","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers","volume":"183","author":"Richmond","year":"2001","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1086\/599347","article-title":"Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis","volume":"49","author":"de Voer","year":"2009","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0140","doi-asserted-by":"crossref","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","article-title":"Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine","volume":"5","author":"de Voer","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0145","doi-asserted-by":"crossref","first-page":"F43","DOI":"10.1136\/fn.74.1.F43","article-title":"Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy","volume":"74","author":"O\u2019Dempsey","year":"1996","journal-title":"Archives of Disease in Childhood. Fetal and Neonatal Edition"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0150","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/INF.0b013e31819040e7","article-title":"The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada","volume":"28","author":"Bettinger","year":"2009","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0155","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1128\/IAI.69.4.2378-2382.2001","article-title":"Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains","volume":"69","author":"Richmond","year":"2001","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0160","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1128\/IAI.71.10.5549-5555.2003","article-title":"Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom","volume":"71","author":"Borrow","year":"2003","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0165","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/INF.0b013e31824f34e6","article-title":"Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom","volume":"31","author":"Findlow","year":"2012","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0170","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CVI.00420-08","article-title":"Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom","volume":"16","author":"Southern","year":"2009","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.vaccine.2005.07.060","article-title":"Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP\/Hib vaccine","volume":"24","author":"Southern","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/INF.0b013e3181b9a831","article-title":"A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months","volume":"29","author":"D\u00edez-Domingo","year":"2010","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0185","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/01.inf.0000227725.61495.c4","volume":"25","author":"Tejedor","year":"2006","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0190","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/INF.0b013e31816b4561","volume":"27","author":"Tejedor","year":"2008","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0195","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1086\/344324","article-title":"Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom","volume":"186","author":"Borrow","year":"2002","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0200","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1016\/j.vaccine.2009.06.049","volume":"27","author":"Kitchin","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0205","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United kingdom primary-school children in 1999\u20132000 and response to a booster: a phase 4 clinical trial","volume":"50","author":"Perrett","year":"2010","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0215","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0220","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/509619","article-title":"Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom","volume":"194","author":"Auckland","year":"2006","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0225","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1371\/journal.pntd.0000342","article-title":"Immunogenicity of fractional doses of tetravalent A\/C\/Y\/W135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda","volume":"2","author":"Guerin","year":"2008","journal-title":"PLOS Neglected Tropical Diseases"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0230","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1016\/j.vaccine.2010.09.092","article-title":"Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2\u201310 years of age","volume":"28","author":"Halperin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0235","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10096-009-0848-8","article-title":"Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers","volume":"29","author":"Halperin","year":"2010","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0240","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents","volume":"6","author":"Gill","year":"2010","journal-title":"Human Vaccines"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0245","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1016\/j.vaccine.2012.02.046","article-title":"Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations","volume":"30","author":"Khatami","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0250","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1097\/INF.0b013e318224fb14","article-title":"Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine","volume":"30","author":"de Whalley","year":"2011","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0255","first-page":"1100","article-title":"Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults","volume":"11","author":"Southern","year":"2004","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0260","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1128\/CVI.00279-08","article-title":"Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era","volume":"15","author":"Trotter","year":"2008","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0265","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0270","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated post-licensure surveillance of meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlate of protection and modelling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0275","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0280","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0285","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands","volume":"25","author":"de Greeff","year":"2006","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0290","first-page":"189","article-title":"Bacteri\u00eble meningitis in Nederland, 2001\u20132010","volume":"22","author":"van der Ende","year":"2011","journal-title":"Infectieziekten Bulletin"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0295","unstructured":"Stoof S, van der Klis F, van Rooijen D, Sanders E, Berbers G. Determining the appropriate age for a second immunization with meningococcal serogroup C conjugate vaccine; an intervention study among Dutch teenagers. 2012; Poster number: P141, in: XVIII International Pathogenic Neisseria Conference (IPNC), September 9\u201314, 2012, W\u00fcrzburg, Germany."},{"key":"10.1016\/j.vaccine.2013.07.083_bib0300","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2807\/esm.09.07.00474-en","article-title":"Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision","volume":"9","author":"Cano","year":"2004","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0305","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/infdis\/167.5.1212","article-title":"Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization","volume":"167","author":"Ceesay","year":"1993","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0310","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/jama.280.19.1685","article-title":"Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial","volume":"280","author":"MacDonald","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0315","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1001\/jama.292.20.2491","article-title":"Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine","volume":"292","author":"De Wals","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0320","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/pch\/16.8.485","article-title":"Meningococcal vaccines in Canada: an update","volume":"16","author":"Savadori","year":"2011","journal-title":"Paediatrics & Child Health"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0325","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/aje\/kwi160","article-title":"Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination","volume":"162","author":"Trotter","year":"2005","journal-title":"American Journal of Epidemiology"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0330","unstructured":"Pollard AJ. Protein-polysaccharide conjugate vaccine failure, 2010, in: 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), May 4\u20138, 2010, Nice, France."},{"key":"10.1016\/j.vaccine.2013.07.083_bib0335","first-page":"1042","article-title":"Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease","volume":"58","year":"2009","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"36","key":"10.1016\/j.vaccine.2013.07.083_bib0340","doi-asserted-by":"crossref","DOI":"10.2807\/ese.17.36.20261-en","article-title":"Community cluster of meningococcal disease by Neisseria meningitidis serogroup C in Andalusia, Spain, March to May 2011","volume":"17","author":"Mayoral Cort\u00e9s","year":"2012","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0345","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1128\/JCM.01322-10","article-title":"Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort","volume":"49","author":"Bidmos","year":"2011","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1016\/j.vaccine.2013.07.083_bib0350","unstructured":"European Medicines Agency. Bexsero. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002333\/human_med_001614.jsp&mid=WC0b01ac058001d124. [accessed 11.03.13]."},{"key":"10.1016\/j.vaccine.2013.07.083_bib0355","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12325-013-0032-5","article-title":"Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, Nimenrix\u2122, a review","volume":"30","author":"Findlow","year":"2013","journal-title":"Advances in Therapy"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13010748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13010748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T15:37:56Z","timestamp":1731339476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13010748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":71,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0264410X13010748"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.07.083","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of meningococcal serogroup C vaccine programmes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.07.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2013 Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}